BioCentury | Nov 30, 2017
Clinical News

Immune Pharmaceuticals reports additional Phase II data for bertilimumab in bullous pemphigoid

...moderate to severe bullous pemphigoid in a Phase II trial showing that IV bertilimumab (CAT-213, iCo-008...
...in the Bullous Pemphigoid Disease Area Index (BPDAI) Total Activity Score of 85% (p=0.0096). Additionally, bertilimumab...
...TSX-V:ICO; OTCQX:ICOTF), Vancouver, B.C. Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP), Englewood Cliffs, N.J. Product: Bertilimumab (CAT-213, iCo-008...
BioCentury | Mar 17, 2017
Clinical News

Bertilimumab: Preliminary Ph II data

...pemphigoid in an open-label, U.S. and Israeli Phase II trial showed that 10 mg/kg IV bertilimumab...
...SSE:IMNP), New York, N.Y. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bertilimumab ( iCo-008 , CAT-213...
...and change in quality of life (QOL) score Status: Preliminary Phase II data Milestone: NA Alicia Parker bertilimumab CAT-213 iCo-008 AstraZeneca...
BioCentury | Sep 12, 2016
Emerging Company Profile

Age factors

...age-related disorders. McCracken would not disclose a development timeline. Immune Pharmaceuticals Inc .'s anti-CCL11 mAb bertilimumab...
...the clinic for autoimmune, inflammatory and hepatic diseases. The biotech has exclusive, worldwide rights to bertilimumab...
...iCo Therapeutics Inc. , which retains rights for ophthalmic indications. McCracken declined to comment on bertilimumab...
BioCentury | Apr 4, 2016
Finance

Restructuring watch

...for bertilimumab (iCo-008). Partner Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP) is conducting Phase II trials of bertilimumab...
BioCentury | Feb 8, 2016
Company News

iCo ophthalmic, autoimmune, infectious news

...4, 2014). The company said it will investigate non-dilutive sources of funding for bertilimumab ( iCo-008...
...Phase I testing to treat HIV infection in 2017. Data from Phase II trials of bertilimumab...
...1H16 and 4Q16, respectively. Immune Pharmaceuticals Inc. (NASDAQ:IMNP; SSE:IMNP, New York, N.Y.) has rights to bertilimumab...
BioCentury | Jul 20, 2015
Clinical News

Bertilimumab: Phase II started

...Immune Pharmaceuticals began an open-label, Israeli Phase II trial to evaluate 2 doses of IV bertilimumab...
...SSE:IMNP), New York, N.Y. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bertilimumab ( iCo-008 , CAT-213...
BioCentury | Sep 29, 2014
Clinical News

Bertilimumab: Phase II started

...double blind, placebo-controlled, Israeli Phase II trial to evaluate 3 doses of 10 mg/kg IV bertilimumab...
...NASDAQ:IMNP; SSE:IMNP), Tarrytown, N.Y. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bertilimumab ( iCo-008 , CAT-213...
BioCentury | Aug 18, 2014
Clinical News

Bertilimumab: Phase II started

...screening in an open-label Phase II trial to evaluate 2 doses of 10 mg/kg IV bertilimumab...
...OTCQX:IMNP; SSE:IMNP), Tarrytown, N.Y. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bertilimumab ( iCo-008 , CAT-213...
BioCentury | Mar 4, 2013
Clinical News

Bertilimumab: Phase II start

...Pharmaceuticals will begin a double-blind, placebo-controlled, international Phase II trial to evaluate 7 mg/kg IV bertilimumab...
...Ltd. , Herzliya-Pituach, Israel AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Bertilimumab ( CAT-213 , iCo-008...
BioCentury | Nov 12, 2012
Company News

EpiCept, Immune Pharmaceuticals deal

...EpiCept's vascular disruptive agents. Immune is initiating a Phase II ulcerative colitis (UC) trial of bertilimumab...
Items per page:
1 - 10 of 23